Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease
O. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), Y. Koh (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), Y. Oh (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lim (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), S. Hong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea)
Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), Y. Koh (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), Y. Oh (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lim (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), S. Hong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea). Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease. 538
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020
The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016 Year: 2017
Factors related to response to intermittent treatment of mycobacterium avium complex lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 557s Year: 2006
Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019
Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients Source: Eur Respir J 2013; 41: 1101-1106 Year: 2013
The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017 Year: 2017
Hospital-based antibiotic use in patients with Mycobacterium avium complex Source: ERJ Open Res, 4 (4) 00109-2018; 10.1183/23120541.00109-2018 Year: 2018
Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease Source: Eur Respir J 2009; 33: 148-152 Year: 2009
The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019 Year: 2020
Clinical features of pulmonary Mycobacterium avium intracellulare complex disease with a solitary pulmonary nodule in Japan Source: Eur Respir J 2005; 26: Suppl. 49, 687s Year: 2005
Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systemic review and meta-analysis Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
Clinical analysis of pulmonary Mycobacterium avium complex disease in Japan Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012
Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course Source: Eur Respir J , 49 (3) 1600537; DOI: 10.1183/13993003.00537-2016 Year: 2017